PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 162
- Registration Number
- NCT00265317
- Locations
- πͺπΈ
Pfizer Investigational Site, Santander, Cantabria, Spain
Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2007-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 324
- Registration Number
- NCT00263874
- Locations
- π¬π§
Pfizer Investigational Site, Manchester, United Kingdom
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
- First Posted Date
- 2005-12-08
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00263328
- Locations
- πΊπΈ
Annette C & Harold C Simmons Transplant Institute, Dallas, Texas, United States
πΊπΈTransplant Research Institute, Los Angeles, California, United States
πΊπΈBalboa Institute of Transplantation, San Diego, California, United States
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 571
- Registration Number
- NCT00261846
- Locations
- πΊπΈ
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
π¨π¦University Health Network Princess Margaret Hospital, Toronto, Ontario, Canada
πΊπΈPenn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Evaluation Of Linezolid Pk Profile In Burns Patients
- Conditions
- Burns
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00255996
- Locations
- π«π·
Pfizer Investigational Site, Paris, France
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: PF-3512676 + Paclitaxel + Carboplatin
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 828
- Registration Number
- NCT00254891
- Locations
- π¬π§
Pfizer Investigational Site, Swansea, United Kingdom
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 839
- Registration Number
- NCT00254904
- Locations
- π¬π§
Pfizer Investigational Site, Wolverhampton, United Kingdom
A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)
- Conditions
- Chronic Bronchitis
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2009-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 398
- Registration Number
- NCT00254566
- Locations
- πΉπ
Pfizer Investigational Site, Khon Kaen, Thailand
Study of SU011248 in Patients With Advanced Kidney Cancer
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: SU011248 capsule
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2010-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51
- Registration Number
- NCT00254540
- Locations
- π―π΅
Pfizer Investigational Site, Yamagata, Japan
A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects
- Conditions
- Healthy Volunteers
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2009-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00251030
- Locations
- πΊπΈ
Pfizer Investigational Site, Kalamazoo, Michigan, United States